April 1 (Reuters) - Mesoblast Ltd MSB.AX :
* U.S. FDA ACCEPTED FOR PRIORITY REVIEW CO'S BIOLOGICS LICENSE APPLICATION FILING FOR RYONCILTM (REMESTEMCEL-L)
April 1 (Reuters) - Mesoblast Ltd MSB.AX :
* U.S. FDA ACCEPTED FOR PRIORITY REVIEW CO'S BIOLOGICS LICENSE APPLICATION FILING FOR RYONCILTM (REMESTEMCEL-L)